All In Biotech

Free tool

FAERS Monitor: Cefazolin Sodium

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 211413 or its brand name (Cefazolin Sodium, Cefazolin Sodium). Reports on generic versions are filed under their own applications.

Reports

12,207

Serious

11,391

93% of reports

Hospitalization

6,181

Death reported

1,402

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • hypotension711
  • drug ineffective679
  • anaphylactic reaction659
  • anaphylactic shock622
  • rash600
  • pyrexia518
  • renal failure488
  • acute kidney injury442
  • off label use424
  • pain417
  • nausea379
  • urticaria361
  • dyspnoea337
  • drug hypersensitivity329
  • erythema320

Reports by year received

View as table
YearReports
2004222
2005210
2006255
2007157
2008238
2009224
2010233
2011507
2012462
2013268
2014304
2015373
2016540
2017510
2018700
2019831
2020855
2021805
2022954
20231,008
2024981
2025956
2026614

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,041,952 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
anaphylactic shockSignal62242.639.424,639
anaphylactic reactionSignal65920.819.312,276
renal failureSignal4886.45.82,201
hypotensionSignal7116.15.73,063
acute kidney injurySignal4425.04.61,412
urticariaSignal3613.73.4719
drug hypersensitivitySignal3292.92.6420
erythemaSignal3202.72.4339
pyrexiaSignal5182.62.4508
rashSignal6002.42.2485
pain4171.21.110
dyspnoea3371.00.90
drug ineffective6790.90.810
off label use4240.80.814
nausea3790.80.714

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.